Literature DB >> 1532486

Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.

L B Heifets1, P J Lindholm-Levy, R D Comstock.   

Abstract

Minimal inhibitory and bactericidal concentrations (MIC and MBC) of clarithromycin were determined with 49 Mycobacterium avium strains isolated from patients with acquired immunodeficiency syndrome. The inhibitory activity depended on the pH of the medium: the drug was more active at pH 7.4 and less active at pH 5.0, with activity at pH 6.8 in an intermediate position. The broth-determined MIC found at pH 7.4 were 0.25 and 0.5 micrograms/ml for most strains. The agar-determined MIC for most strains ranged from 1.0 to 4.0 micrograms/ml. The MBC of the drug were 8- to 64-fold higher than the MIC, which indicates that the efficacy of clarithromycin can be associated with its inhibitory rather than its bactericidal activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532486     DOI: 10.1164/ajrccm/145.4_Pt_1.856

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  39 in total

1.  In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare.

Authors:  L Steele-Moore; K Stark; W J Holloway
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium.

Authors:  L B Heifets; P J Lindholm-Levy; R D Comstock
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

3.  Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

4.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

5.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.

Authors:  Gail L Woods; Natalie Williams-Bouyer; Richard J Wallace; Barbara A Brown-Elliott; Frank G Witebsky; Patricia S Conville; Marianne Plaunt; Geraldine Hall; Priscilla Aralar; Clark Inderlied
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

7.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare.

Authors:  A Meier; P Kirschner; B Springer; V A Steingrube; B A Brown; R J Wallace; E C Böttger
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits.

Authors:  M Emori; H Saito; K Sato; H Tomioka; T Setogawa; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

Authors:  L E Bermudez; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.